Document is current
Any future updates will be listed below
-
Authors
Kamii, Misato
Kamata, Ryo
Saito, Hitoshi
Yamamoto, Gaku
Mashima, Chiaki
Yamauchi, Toyohiro
Nakao, Takehiro
Sakae, Yuta
Yamamori-Morita, Tomoko
Nakai, Kazuki
Hakozaki, Yumi
Takenaka, Masataka
Okamoto, Aikou
Ohashi, Akihiro
-
Funding
Funding for this research was provided by:
Grants-in-Aid for Scientific Research (23K06708)
the Grants-in-Aid for Scientific Research (20H03541, 20H03541)
Grant-in-Aid for Research Activity Start-up (24K23370)
Grants-in-Aid for Fostering Joint International Research (20KK0187)
Takeda Science Foundation
- License Information
-
More Information
Article History
Received: 10 January 2025
Accepted: 28 April 2025
First Online: 2 May 2025
Declaration
:
: T.Y. was an employee of Axcelead Drug Discovery Partners, Inc (2023-present). A.Oh. was an employee of Takeda Pharmaceutical Company, Ltd (2006–2018). A.Oh. is a part-time employee of Astellas Pharma Inc. as a cross-appointment system (2022-present). A.Oh. reported paid consulting or advisory roles for Ono Pharmaceutical Company Ltd., Craif Inc., and GEXVal Inc. out of this study. A.Oh. has received research funding from Takeda Pharmaceutical, Daiichi-Sankyo, and Astellas Pharma companies out of this study. M.K., R.K., H.S., G.Y., C.M., T.N., Y.S., T.Y.M, K.N., Y.H., M.T., and A.O. declare no competing interests.
